Advertisement

Topics

Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A

08:55 EDT 10 Aug 2017 | SCRIP

Aurobindo Pharma reported a subdued Q1 but investors remained upbeat on the firm’s prospects as it transitions to a larger...

      

Related Stories

 

Original Article: Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A

NEXT ARTICLE

More From BioPortfolio on "Muted Q1 For Aurobindo But Outlook Firm; Don’t Expect ‘Exotic’ M&A"

Quick Search
Advertisement